China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included as the first recommended treatment for second-line recurrent or metastatic cervical cancer in the Chinese Society of Clinical Oncology’s (CSCO) cervical cancer diagnosis and treatment guidelines (2022). This marks a significant milestone in the recognition and adoption of cadonilimab in clinical practice.
Cadonilimab: Drug Profile and Development
Cadonilimab is an innovative bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It was first conditionally approved in China in June 2022 for the treatment of patients with recurrent or metastatic cervical cancer who previously failed platinum-based chemotherapy. As the global first-in-class PD-1/CTLA-4 BsAb, cadonilimab represents a significant advancement in the treatment of cervical cancer.
Clinical Studies and Future Outlook
Cadonilimab is currently undergoing a Phase III clinical study in first-line recurrent or metastatic cervical cancer, in combination with platinum-based chemotherapy and bevacizumab. Additionally, it is being evaluated in a Phase III study in combination with concurrent chemotherapy and radiotherapy for locally advanced cervical cancer. These studies aim to further validate the efficacy and safety of cadonilimab in different treatment settings.
The inclusion of cadonilimab in the CSCO guidelines underscores its potential to improve outcomes for patients with recurrent or metastatic cervical cancer. Akeso Biopharma continues to advance its clinical programs, positioning cadonilimab as a leading treatment option in the field of oncology.-Fineline Info & Tech
